MétaCan
Menu
Back to cohort
Record W4409637253 · doi:10.1158/1538-7445.am2025-6919

Abstract 6919: Targeting CLIC3 as a novel strategy to inhibit metastasis in breast cancer

2025· article· en· W4409637253 on OpenAlexaff
Paul Mellor, Stephanie Kendall, Shari Smith, Jonas Olsen, Henok Sahile, Brent D. G. Page, Anurag Saxena, Deborah H. Anderson

Bibliographic record

VenueCancer Research · 2025
Typearticle
Languageen
FieldMedicine
TopicCancer Treatment and Pharmacology
Canadian institutionsUniversity of British ColumbiaSaskatchewan Cancer AgencyUniversity of Saskatchewan
Fundersnot available
KeywordsBreast cancerMetastasisMedicineCancerBreast cancer metastasisCancer researchOncologyInternal medicineCancer metastasis

Abstract

fetched live from OpenAlex

Abstract Women with metastatic breast cancer have a 5-year survival rate of only 28%. This study aims to investigate the role of CLIC3 (chloride intracellular channel 3) in breast cancer metastasis and explore its potential as a therapeutic target. CLIC3, secreted by cancer cells and cancer-associated fibroblasts, promotes tumor invasion and angiogenesis through its oxidoreductase activity that inhibits TGM2 (transglutaminase-2). High CLIC3 levels correlate with poor prognosis across all breast cancer subtypes. CLIC3 was knocked down in metastatic breast cancer cells, which were evaluated for cell migration and invasion using Boyden chambers, non-adherent growth in soft agar, and tumor formation and metastasis in mice. Small molecule inhibitors of CLIC3 activity were identified using an in silico screen of >10 million commercially available small molecules and 94 compounds were tested as possible CLIC3 inhibitors (CLIC3i) using recombinant CLIC3. We synthesized over 70 analogs of the top inhibitor for structure-activity relationship analysis, with the most promising inhibitors also assessed for CLIC3 binding using thermal shift assays and migration in scratch assays. CLIC3 knockdown significantly reduced cell migration, invasion, and growth in soft agar, effects rescued by shRNA-insensitive CLIC3. In vivo, CLIC3 knockdown decreased tumor growth and completely blocked lung metastasis, underscoring its role in the colonization and growth of macroscopic metastases. Four promising compounds with mid-μM IC50 values for CLIC3 activity inhibition were identified (E5, D1, A5, D5). Among them, HA-22-31 emerged as a lead compound (IC50 = 1.7 μM), demonstrating direct binding to CLIC3 and significant inhibition of migration. In conclusion, CLIC3 enhances metastasis in breast cancer through its enzymatic activity. These findings suggest that further development of small molecule CLIC3 inhibitors may represent a promising new strategy for targeting metastatic breast cancer. Citation Format: Paul Mellor, Stephanie Kendall, Shari Smith, Jonas Olsen, Henok Sahile, Brent Page, Anurag Saxena, Deborah Anderson. Targeting CLIC3 as a novel strategy to inhibit metastasis in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6919.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.013

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.118
GPT teacher head0.514
Teacher spread0.397 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicCancer Treatment and PharmacologyFrench-language works237,207